3rd Quarter - Report

SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$550,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report (this page) Oct 20, 2017 $550,000 Replaced
3rd Quarter - Amendment Jul 24, 2018 $550,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Orphan drug tax credit Corporate Tax Reform

LobbyistCovered position, as disclosed
MARK LENKER —
JED PERRY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing

LobbyistCovered position, as disclosed
ENGEL BURNS —
MARK LENKER —
JED PERRY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - Affordable Care Act Medicaid Expansion - Medicare IVIG Access Act Reauthorization HR 3172 - Medicare Part D

LobbyistCovered position, as disclosed
ENGEL BURNS —
JED PERRY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 6 (115th), H.R. 3172 (115th)

Pharmacy PHA

ADHD Awareness *Drug Values -Binge Eating Disorder awareness -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy Patient access to therapy, including Medicaid, Medicare, and insurance. -Orphan Drug Act regulations -HR 1628 - American Health Care Act of 2017 American Health Care Act of 2017/Better Care Reconciliation Act (H.R. 1628), including patient access, needs for rare disease patients, coverage issues, pre-existing conditions, lifetime and annual caps, essential health benefits, Medicaid, reimbursement, and insurance. -PDUFA Reauthorization The Food and Drug Act Reauthorization Act (FDARA) of 2017 (H.R. 2430 and S. 934), including the PDUFA Reauthorization, RACE for Children Act, Right-to-Try, expanded access, clinical superiority standards, drug access and values, off-label communications, pediatric labeling and generic drugs, and drug importation. -Expanded Access -NIH funding, including expansion for rare diseases -Rare Disease awareness -RACE for Children Act (S. 456 and H.R. 1231) -Right to Try legislation (S. 204, H.R. 878, and H.R. 2368) -Pharmaceutical Information Exchange Act (H.R. 2026) -Drug Diversion and Counterfeit Crackdown Act of 2017 (H.R. 2376) -Medical Product Communications Act (H.R. 1703) -Newborn Screening -Study eligibilities for DOD PRMRP

LobbyistCovered position, as disclosed
MARK LENKER —
JED PERRY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2026 (115th), H.R. 1703 (115th), H.R. 2368 (115th), H.R. 1231 (115th), H.R. 2376 (115th), H.R. 1628 (115th), H.R. 878 (115th), S. 204 (115th), S. 456 (115th), S. 934 (115th), H.R. 2430 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.